SANTA MONICA, Calif., Feb. 2, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that Arie Belldegrun, M.D., FACS, Kite's President and Chief Executive Officer, will present a corporate overview at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, 2015 at 1:30 p.m. Eastern Time at the Waldorf Astoria in New York City. Dr. Belldegrun will also take part in the panel Personalizing Oncology Treatments at 8:00 a.m. Eastern Time, on the same day.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ peripheral blood product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com.
CONTACT: Kite Contacts:
SVP, Corporate Communications and Investor Relations
For Media: Justin Jackson
For Investor Inquiries: Nancy Yu
Source: Kite Pharma, Inc.
News Provided by Acquire Media